{"entity":{"id":"rejuv-frontier-mesenchymal-stromal-cells","kind":"technology","name":"Mesenchymal stromal cells for tissue damage","aka":[],"tldr":"There is one licensed mesenchymal cell product in oncology and it is for one narrow use: children whose graft-versus-host disease has not responded to steroids. Everything else sold as a mesenchymal or stromal cell infusion for repair or rejuvenation is unlicensed and untested, and it is worth knowing the difference because the clinics rely on it being blurred.","summary":"Remestemcel-L-rknd (Ryoncil) is a bone-marrow-derived mesenchymal stromal cell product approved by the FDA in December 2024 for steroid-refractory acute graft-versus-host disease in children aged 18 and under, with reported response rates of about 70 per cent and about 70 per cent survival at six months. Before it, ruxolitinib was the only approved option in that setting and only for people over 12. It is given in a transplant centre, under a licence, with the manufacturing controlled.\n\nThat is the whole of the approved evidence. Mesenchymal stromal cells have been trialled for radiation injury, osteonecrosis, fistula, cardiac and neurological damage with mixed and mostly small results, and the field's recurring problem is that 'mesenchymal stromal cell' names a preparation rather than a defined product: source tissue, passage number, culture conditions and potency assays differ between every manufacturer, so trials are not comparable.\n\nIn the UK a cell therapy is an advanced therapy medicinal product, and the MHRA states that all such products placed on the market must have a marketing authorisation; the hospital exemption covers products prepared non-routinely for a named patient in a hospital and still needs a manufacturer's licence. A clinic offering an infusion outside that framework is not operating in a grey area.","status":"approved","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Mesenchymal_stem_cell","links":[{"label":"Kean, Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD (Blood 2025)","url":"https://doi.org/10.1182/blood.2025028553"},{"label":"Remestemcel-L-rknd for steroid-refractory acute graft-vs-host disease in pediatric patients (JAMA 2025)","url":"https://doi.org/10.1001/jama.2025.6179"},{"label":"MHRA: Advanced therapy medicinal products, regulation and licensing in the UK","url":"https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk"}],"tags":["rejuvenation","survivorship","evidence:moderate","cell-therapy"],"related":["rejuv-frontier-stem-cell-tourism"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":["allogeneic-hsct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["late-effects"],"trials":[],"people":[],"bottlenecks":["b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Mesenchymal stromal cells are immunomodulatory rather than regenerative in most settings: they secrete prostaglandin E2, indoleamine 2,3-dioxygenase and TGF-beta, and they reprogramme macrophages, which is why the one approved indication is an immune complication rather than a structural repair.","strengths":["One FDA-approved product with a defined indication, manufacturing standard and reported response rate","Fills a real gap for children with steroid-refractory acute graft-versus-host disease","Immunomodulatory mechanism is reasonably well characterised"],"limitations":["Approved for one indication in one age group; everything else is investigational","Products from different manufacturers are not interchangeable and trials are not comparable","No evidence for infusions sold to survivors for repair, energy or rejuvenation","Unlicensed supply is outside the ATMP framework in the UK and outside FDA approval in the US"]},"route":"/technologies/rejuv-frontier-mesenchymal-stromal-cells/","neighbours":{"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"rejuv-frontier-stem-cell-tourism","kind":"technology","name":"Stem cell clinics and stem cell tourism","route":"/technologies/rejuv-frontier-stem-cell-tourism/"},{"id":"rejuv-frontier-what-works","kind":"technology","name":"What actually works after treatment","route":"/technologies/rejuv-frontier-what-works/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"term":[{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"}],"bottleneck":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}]}}